With the recent $43B acquisition of Seagen, Pfizer is poised to be one of the leading Pharmaceuticals targeting oncology in the very near future. Patent expiration is looming with several key established drugs in their pipeline. They've taken an offensive big step in securing a global presence in the space. -Kmall
https://www.fiercepharma.com/pharma/pfi ... drugs-2030
Pfizer's big push into the Oncology space
Forum rules
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
Re: Pfizer's big push into the Oncology space
Imetelstat works (safe and effective) and is proven for blood cancers in a variety of ways (note KOLs and ODAC meeting March 14th).
Pfizer's acquisition ($43B) will increase the interest in and value of Imetelstat. The potential in combinations and chemotherapy is vast for many cancers, both blood cancers and solid cancers. Once approved (NDA for blood transfusions) new trials and off-label uses will come into focus. The Cancer Moonshot is ongoing.
======================
Pfizer's acquisition ($43B) will increase the interest in and value of Imetelstat. The potential in combinations and chemotherapy is vast for many cancers, both blood cancers and solid cancers. Once approved (NDA for blood transfusions) new trials and off-label uses will come into focus. The Cancer Moonshot is ongoing.
======================
With the recent $43B acquisition of Seagen, Pfizer is poised to be one of the leading Pharmaceuticals targeting oncology in the very near future. --- from Kmall